CVS Health has lagged the S&P over the past month (+1.6% vs. +4.1%) while its pharmacy sector has plunged (~-16.3%); aggressive sell-side earnings downgrades have driven a negative near‑term outlook—quarterly EPS is now expected at $1.82 (-17.7% y/y; consensus down ~17.8% in 30 days), fiscal‑year EPS $7.24 (-17.2%), and next‑fiscal EPS $7.81 (+7.9% y/y but recently cut). The company reported last quarter revenue of $88.44B (+3.7% y/y) and EPS of $1.31 (vs. $2.20 a year ago), missing estimates on both lines (EPS surprise -22.5%, revenue surprise -0.86%), and while Zacks flags CVS with a Value score of A (trading at a discount to peers), the scale of earnings revisions has produced a Zacks Rank #5 (Strong Sell), implying potential near‑term underperformance despite the valuation cushion.
Shares of CVS Health returned +1.6% over the past month versus the S&P 500's +4.1%, while the Zacks Retail - Pharmacies and Drug Stores industry fell ~16.3%, signaling sector-specific weakness despite modest outperformance versus peers. Zacks notes steep downward revisions to earnings: current-quarter EPS is forecast at $1.82 (-17.7% y/y) with the 30‑day consensus down 17.8%, fiscal‑year EPS $7.24 (-17.2%, -15.5% in 30 days) and next fiscal year $7.81 (+7.9% but cut -14% in the past month). Last reported quarter showed revenue of $88.44B (+3.7% y/y) versus a $89.2B consensus (-0.86% surprise) and EPS of $1.31 vs. $2.20 a year ago (EPS surprise -22.49%), while CVS has beaten EPS and revenue consensus three of the past four quarters. Valuation metrics earn a Zacks Value grade A (trading at a discount to peers), but the magnitude of recent estimate cuts has produced a Zacks Rank #5 (Strong Sell), implying likely near‑term underperformance until estimate trends reverse and upcoming quarterly results provide clearer guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
